ValuEngine Lowers Biohaven Pharmaceutical (NYSE:BHVN) to Sell

Share on StockTwits

ValuEngine lowered shares of Biohaven Pharmaceutical (NYSE:BHVN) from a hold rating to a sell rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald lifted their target price on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the company an overweight rating in a research note on Monday, October 28th. William Blair reissued a buy rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, September 17th. Oppenheimer set a $67.00 target price on Biohaven Pharmaceutical and gave the company a buy rating in a research note on Wednesday, October 9th. Goldman Sachs Group set a $89.00 target price on Biohaven Pharmaceutical and gave the company a buy rating in a research note on Wednesday, September 4th. Finally, Zacks Investment Research cut Biohaven Pharmaceutical from a buy rating to a hold rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $71.80.

Shares of NYSE BHVN traded up $2.06 during midday trading on Thursday, hitting $51.08. The stock had a trading volume of 881,221 shares, compared to its average volume of 487,177. The company’s 50-day simple moving average is $45.01 and its 200 day simple moving average is $47.68. The firm has a market cap of $2.56 billion, a P/E ratio of -8.31 and a beta of 0.34. Biohaven Pharmaceutical has a fifty-two week low of $29.17 and a fifty-two week high of $67.86.

Biohaven Pharmaceutical (NYSE:BHVN) last released its earnings results on Friday, November 1st. The company reported ($2.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.47). On average, sell-side analysts forecast that Biohaven Pharmaceutical will post -7.57 earnings per share for the current fiscal year.

In other Biohaven Pharmaceutical news, Director Eric Aguiar sold 10,000 shares of Biohaven Pharmaceutical stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $45.00, for a total transaction of $450,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Elyse Stock sold 800 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $45.01, for a total value of $36,008.00. Following the transaction, the insider now owns 800 shares in the company, valued at $36,008. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,500 shares of company stock valued at $1,283,747. 23.90% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of BHVN. Marshall Wace LLP bought a new position in Biohaven Pharmaceutical during the first quarter worth about $365,000. Xact Kapitalforvaltning AB bought a new position in Biohaven Pharmaceutical during the second quarter worth about $320,000. Handelsbanken Fonder AB bought a new position in Biohaven Pharmaceutical during the second quarter worth about $6,656,000. Clear Street Markets LLC bought a new position in Biohaven Pharmaceutical during the second quarter worth about $335,000. Finally, Fox Run Management L.L.C. bought a new position in Biohaven Pharmaceutical during the second quarter worth about $434,000. Hedge funds and other institutional investors own 88.91% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: Earnings Reports

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

United Natural Foods  Shares Gap Down  Following Weak Earnings
United Natural Foods Shares Gap Down Following Weak Earnings
Fortuna Silver Mines Inc  Short Interest Up 19.5% in November
Fortuna Silver Mines Inc Short Interest Up 19.5% in November
First Bancorp  Sees Large Growth in Short Interest
First Bancorp Sees Large Growth in Short Interest
Ted Baker’s  “Under Review” Rating Reaffirmed at Panmure Gordon
Ted Baker’s “Under Review” Rating Reaffirmed at Panmure Gordon
SSE  Receives Neutral Rating from UBS Group
SSE Receives Neutral Rating from UBS Group
RSA Insurance Group  Receives “Outperform” Rating from Royal Bank of Canada
RSA Insurance Group Receives “Outperform” Rating from Royal Bank of Canada


© 2006-2019 Ticker Report